Actively Recruiting

Age: 18Years +
All Genders
ID07389408

A Prospective, Multicenter Registry to Observe Treatment Patterns, Clinical Outcomes, and Decision-Making in Early Breast Cancer Eligible for EndoPredict4 Testing

Led by National and Kapodistrian University of Athens · Updated on 2026-02-05

2000

Participants Needed

13

Research Sites

561 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are observing and documenting treatment decisions, protocols, and clinical outcomes in patients with luminal (ER-positive/HER2-negative) early breast cancer who are eligible for EndoPredict4 testing. This prospective, multicenter, non-interventional registry includes patients who undergo EndoPredict testing and those who do not, aiming to understand real-world treatment patterns and long-term results. Participants have non-metastatic invasive breast cancer with tumor size T1 to T3 and 0 to 3 positive axillary lymph nodes. This observational study does not change patient treatment. Patients may enroll after surgery and before starting adjuvant endocrine therapy. The registry is conducted across multiple sites, mainly in Greece, with plans to enroll up to 2,000 participants over 3 years. Participants will be followed once yearly for up to 10 years after surgery. Researchers will collect data on clinical outcomes such as distant relapse-free survival, overall survival, and local relapse-free survival at 5 and 10 years. They will also evaluate how EndoPredict risk scores relate to treatment decisions and outcomes, alongside patient and disease characteristics influencing therapy choices.

CONDITIONS

Brief Title

A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Histological diagnosis of invasive breast cancer
  • Tumor size T1 to T3
  • 0 to 3 positive axillary lymph nodes
  • ER-positive tumor confirmed by immunohistochemistry (≥1% or Allred Score ≥3/8 or H-score ≥50/300)
  • HER2-negative tumor confirmed by immunohistochemistry and/or in situ hybridization
  • Signed and dated informed consent form
Not Eligible

You will not qualify if you...

  • History of another primary cancer within the last 5 years, except for successfully treated non-melanoma skin cancer
  • Received chemotherapy before surgery
  • No signed and dated informed consent form

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surveillance

Duration - Up to 10 years after surgery

Participants who underwent surgery are observed and followed prospectively to assess treatment patterns, clinical outcomes, and decision-making in early breast cancer.

Annual visits for up to 10 years

Trial Site Locations

Total: 13 locations

1

"Elena Venizelou" General Hospital, Department of Surgery

Athens, Greece

Actively Recruiting

2

"Prolipsis" Center, Breast Unit

Athens, Greece

Actively Recruiting

3

Henry Dunant Hospital Center, 3rd Breast Surgical Department

Athens, Greece

Actively Recruiting

4

Laiko Hospital, National and Kapodistrian University of Athens, Medical School

Athens, Greece

Actively Recruiting

5

Mediterraneo Hospital, Breast Clinic

Athens, Greece

Actively Recruiting

6

Metropolitan General Hospital, 3rd Breast Clinic

Cholargós, Greece

Actively Recruiting

7

Metropolitan General Hospital, 4th Breast Clinic

Cholargós, Greece

Actively Recruiting

8

"Apollonio-Theotokos" General Clinic, Department of Surgery

Larissa, Greece

Actively Recruiting

9

IASO Thessalias General Clinic, Breast Surgery Department

Larissa, Greece

Actively Recruiting

10

IASO General Clinic, 2nd Breast Clinic

Marousi, Greece

Actively Recruiting

11

MITERA, 1st Breast Clinic

Marousi, Greece

Actively Recruiting

12

Thessaloniki Bioclinic Hospital, Breast Unit

Thessaloniki, Greece

Actively Recruiting

13

General Hospital of Trikala, Breast Surfery Dept.

Trikala, Greece

Actively Recruiting

Loading map...

Research Team

M

Michalis Kontos

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Investigating The Role of Key Non-coding RNA(s) in Breast Ca...

Breast Cancer

Actively Recruiting

1 location

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Bre...

Breast Cancer

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here